Anthera Pharmaceuticals, Inc.
ANTH
$0.00
$0.000.00%
OTC PK
| 03/31/2018 | 12/31/2017 | 09/30/2017 | 06/30/2017 | 03/31/2017 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -3.03% | -29.29% | -56.70% | -39.91% | -19.98% |
| Gross Profit | 3.03% | 29.29% | 56.70% | 39.91% | 18.76% |
| SG&A Expenses | 20.67% | -57.37% | -27.72% | -36.92% | 29.71% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.46% | -36.52% | -52.33% | -39.37% | -10.61% |
| Operating Income | -3.46% | 36.52% | 52.33% | 39.37% | 9.50% |
| Income Before Tax | 31.08% | 25.51% | 61.72% | 102.18% | 4.43% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 31.08% | 25.51% | 61.72% | 102.18% | 4.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 31.08% | 25.51% | 61.72% | 102.18% | 4.43% |
| EBIT | -3.46% | 36.52% | 52.33% | 39.37% | 9.50% |
| EBITDA | -2.38% | 36.65% | 52.30% | 40.18% | 9.33% |
| EPS Basic | 79.40% | 74.21% | 88.13% | 101.11% | 13.41% |
| Normalized Basic EPS | 77.79% | 70.03% | 81.78% | 101.10% | 33.01% |
| EPS Diluted | 79.40% | 74.21% | 88.13% | 101.11% | 13.41% |
| Normalized Diluted EPS | 77.79% | 70.03% | 81.78% | 101.10% | 33.01% |
| Average Basic Shares Outstanding | 227.93% | 148.54% | 110.11% | 97.62% | 35.02% |
| Average Diluted Shares Outstanding | 227.93% | 148.54% | 110.11% | 97.62% | 35.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |